BWCS
HRTX icon

Beirne Wealth Consulting Services’s Heron Therapeutics HRTX Stock Holding History

Beirne Wealth Consulting Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,500
Closed -$196K – 120
2021
Q2 		$196K Hold
12,500
– – 0.11% 107
2021
Q1 		$203K Sell
12,500
-10,000
-44% -$178K 0.12% 97
2020
Q4 		$476K Hold
22,500
– – 0.24% 75
2020
Q3 		$333K Buy
+22,500
New +$351K 0.19% 88

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Beirne Wealth Consulting Services's HRTX Position: Q3 2021 in Review

Beirne Wealth Consulting Services sold out of Heron Therapeutics (HRTX) in Q3 2021, closing a stake of 12,500 shares — an estimated $196K sold.

Beirne Wealth Consulting Services first reported a position in HRTX in Q3 2020 and held it in 4 quarters. The position peaked at $476K in Q4 2020. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

  • Beirne Wealth Consulting Services reported no remaining Heron Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Beirne Wealth Consulting Services sold 12,500 Heron Therapeutics shares in Q3 2021, an estimated $196K.
  • Beirne Wealth Consulting Services first reported a position in Heron Therapeutics in Q3 2020 and held it in 4 quarters.
  • Beirne Wealth Consulting Services's Heron Therapeutics position peaked at $476K in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Beirne Wealth Consulting Services's 13F filing for Q3 2021, filed 9 Nov 2021.